Biosimilars framework for commissioners outlines opportunities for the NHS
NHS England have published the Commissioning framework for biological medicines
NHS England have published the Commissioning framework for biological medicines to make the most of the opportunity presented by increased competition amongst biological medicines, including biosimilar medicines. In particular, the framework sets out the importance of taking a collaborative approach to the commissioning of biological medicines, including biosimilar medicines, as well as setting out how this can be achieved.
RPS Deputy Chief Scientist Claire Thompson said:
“The biosimilars framework announced by NHS England recently will help provide a guide to ensuring the NHS gets best value for money from these innovative, exciting medicines. Biosimilars have demonstrated the same efficacy and same high levels of safety and quality as the originator biological, so patients can be confident they are getting the best treatment. Biosimilars are currently achieving savings in the order of 25-50% of the biological originator. “The reduced costs associated with the use of a biosimilar means that it will be possible to free up money for other medicines or to treat more patients, which is great news.”